Enovis Co. (NYSE:ENOV) Stock Position Increased by Royce & Associates LP

Royce & Associates LP grew its stake in shares of Enovis Co. (NYSE:ENOV) by 2.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,470,576 shares of the company’s stock after acquiring an additional 66,891 shares during the quarter. Enovis comprises about 1.0% of Royce & Associates LP’s investment portfolio, making the stock its 4th biggest holding. Royce & Associates LP owned 4.35% of Enovis worth $108,409,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. State of New Jersey Common Pension Fund D grew its position in Enovis by 15.4% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 43,404 shares of the company’s stock worth $1,869,000 after purchasing an additional 5,801 shares during the period. Victory Capital Management Inc. boosted its stake in shares of Enovis by 14.3% in the 3rd quarter. Victory Capital Management Inc. now owns 32,846 shares of the company’s stock worth $1,414,000 after buying an additional 4,099 shares during the last quarter. Oppenheimer Asset Management Inc. grew its holdings in shares of Enovis by 19.8% in the third quarter. Oppenheimer Asset Management Inc. now owns 11,829 shares of the company’s stock worth $509,000 after acquiring an additional 1,953 shares during the period. Natixis Advisors LLC purchased a new stake in Enovis during the third quarter valued at $546,000. Finally, Mutual of America Capital Management LLC increased its position in Enovis by 5.6% during the third quarter. Mutual of America Capital Management LLC now owns 30,183 shares of the company’s stock valued at $1,299,000 after acquiring an additional 1,604 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Needham & Company LLC dropped their target price on Enovis from $65.00 to $64.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th.

Enovis Trading Up 3.4 %

Shares of Enovis stock opened at $37.01 on Friday. Enovis Co. has a 1-year low of $35.14 and a 1-year high of $62.79. The company’s fifty day simple moving average is $43.32 and its 200-day simple moving average is $43.73. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The stock has a market capitalization of $2.11 billion, a PE ratio of -16.90 and a beta of 2.05.

Enovis (NYSE:ENOV) last released its earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.06. The company had revenue of $560.98 million for the quarter, compared to the consensus estimate of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. As a group, equities analysts anticipate that Enovis Co. will post 2.79 earnings per share for the current year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.